in an article Prostate cancer and prostatic diseaseInvestigators evaluated incremental diagnostic value 18F-DCFPyL, an imaging agent, in dual-stage PET/CT imaging in prostate cancer (PC) patients. According to co-primary investigators, Aijuan Tian, Runlong Lin and Jing Yu,” 18There was an increase in -DCFPyL over time in malignant lesions involving the prostate compared with benign tissue.”
Specifically, to guide with PET/CT imaging 18F-DCFPYL, the researchers stated that “2 hours (delayed) imaging has superior diagnostic performance” for one-time PET/CT imaging; “However, dual-stage imaging (1 and 2h) is helpful in the differential diagnosis of prostate-associated malignant lesions and benign lesions,” he said.
retrospective analysis design
This retrospective analysis was performed on 114 prostate-related malignant lesions and 43 benign lesions in 38 patients with PC. Participants’ maximum standardized uptake values (SUVs) for benign and prostate-related malignant lesions were measured with PET/CT imaging at 60 and 120 min. The authors also calculated the SUV ratio of the left gluteus maximus to the maximal SUV, which was measured concurrently. These values were used to compare the difference between benign and malignant lesions in maximum SUV metrics and SUV ratio, with the clinical efficacy of both measures assessed via a receiver operating curve (ROC) graph. Was.
According to the article, the maximum SUV metrics and SUV ratio of both early and delayed imaging of PC-related malignant lesions were significantly higher than those of benign lesions (p < 0.05). The authors reported that, "in terms of individual indicators, the highest accuracy and sensitivity were in the delayed SUV ratio (89.2% and 94.7%)," although the initial maximum SUV measures had the best specificity (93.0%). Additionally, when individual and combined indicators were compared, the delayed SUV ratio retained the highest diagnostic sensitivity and accuracy, whereas maximum initial SUV, change in maximum SUV and RI value exhibited the best specificity.
In their closing, the authors highlighted that 18F-DCFPYL appears to increase over time in prostate-related malignant lesions, leading to a delay in PET/CT scanning, which has a high diagnostic value. However, they supported the value of multi-stage imaging, noting that it improves the differentiation of malignant and benign lesions.
Read the latest research at DocWire’s Prostate Cancer Resource Center.